Metastatic Triple Negative Breast Cancers (DBCOND0142223)

Identifiers

Synonyms

Triple Negative Breast Cancer Metastatic / Triple-negative Metastatic Breast Cancer / Metastatic Breast Cancer, Triple Negative Breast Cancer / Triple Negative Metastatic Breast Cancer / Metastatic Triple-negative Breast Cancer / Metastatic Triple Negative Breast Cancer / Metastatic Triple-Negative Breast Carcinoma / Triple negative malignant neoplasm of breast (disorder) / Triple Negative Breast Neoplasms / Triple negative breast cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Sacituzumab govitecan	Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.	Tumor-associated calcium signal transducer 2target DNA topoisomerase 1target Far upstream element-binding protein 1target UDP-glucuronosyltransferase 1A1enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05035745	Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)	Selinexor Talazoparib	treatment	1 / 2	recruiting
NCT05582538	Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel	Ceralasertib Durvalumab Paclitaxel	treatment	2	recruiting
NCT03012477	CISPLATIN + AZD-1775 In Breast Cancer	Adavosertib Cisplatin	treatment	2	completed
NCT01881230	Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Carboplatin Gemcitabine Paclitaxel	treatment	2 / 3	completed
NCT02358200	Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer	Carboplatin Paclitaxel Talazoparib	treatment	1	terminated
NCT01069796	Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer	Bevacizumab Capecitabine Paclitaxel	treatment	2	terminated
NCT01576666	Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors	Buparlisib Sonidegib	other	1	completed
NCT00516724	Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel	Carboplatin Olaparib Paclitaxel	treatment	1	completed
NCT05089643	Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer	No drug interventions	treatment	2	unknown_status
NCT03004183	SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC	Nalotimagene carmaleucel Pembrolizumab Valaciclovir	treatment	2	completed
NCT04454437	Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments	Sacituzumab govitecan	treatment	2	active_not_recruiting
NCT04250818	Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile	No drug interventions	Not Available	Not Available	suspended
NCT05227664	A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer	Ivonescimab Ligufalimab Paclitaxel	treatment	2	unknown_status
NCT05831553	TIP in Patients Affected by Metastatic TNBC	No drug interventions	Not Available	Not Available	recruiting
NCT05570253	A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer	Eribulin Evexomostat	treatment	2	recruiting
NCT05746728	Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer	Surufatinib Tislelizumab	treatment	1 / 2	not_yet_recruiting
NCT04986852	Olinvacimab With Pembrolizumab in Patients With mTNBC	Olinvacimab Pembrolizumab	treatment	2	recruiting
NCT05101096	Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors	Sacituzumab govitecan	treatment	1 / 2	recruiting
NCT06027268	Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer	No drug interventions	treatment	2	recruiting
NCT03121352	Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer	Carboplatin Paclitaxel Pembrolizumab	treatment	2	completed
NCT02555657	Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)	Capecitabine Eribulin Gemcitabine Pembrolizumab Vinorelbine	treatment	3	completed
NCT04149444	A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer	TAS-102 Tipiracil Trifluridine	treatment	2	withdrawn
NCT03256344	Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases	Atezolizumab Talimogene laherparepvec	other	1	completed
NCT03709446	Leflunomide in Previously Treated Metastatic Triple Negative Cancers	Leflunomide	treatment	1 / 2	recruiting
NCT03577743	Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer	Bevacizumab	treatment	2	completed
NCT02834403	L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients	Acetylsalicylic acid Amlodipine Docetaxel Pegfilgrastim Tilarginine	treatment	1 / 2	completed
NCT03330847	To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.	Adavosertib Ceralasertib Menthol Olaparib	treatment	2	active_not_recruiting
NCT03411161	S 81694 Plus Paclitaxel in Metastatic Breast Cancer	Paclitaxel	treatment	1 / 2	completed
NCT01936961	Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors	No drug interventions	treatment	Not Available	withdrawn
NCT02158507	Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer	Lapatinib Veliparib	treatment	Not Available	active_not_recruiting
NCT01238952	Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer	Carboplatin SN-38	treatment	1	completed
NCT04739670	Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer	Atezolizumab Bevacizumab Carboplatin Gemcitabine	treatment	2	recruiting
NCT03055312	Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer	No drug interventions	prevention	3	terminated
NCT05008510	P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .	No drug interventions	treatment	2	withdrawn
NCT04111510	Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	2	completed
NCT06434064	Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT05741164	Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	No drug interventions	treatment	1	active_not_recruiting
NCT02595905	Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases	Chloride ion Cisplatin Platinum Veliparib	treatment	2	active_not_recruiting
NCT06176261	DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs	Datopotamab deruxtecan	treatment	2	recruiting
NCT02971761	Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer	Enobosarm Pembrolizumab	treatment	2	completed
NCT03853707	Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer	Atezolizumab Capecitabine Carboplatin Ipatasertib Paclitaxel	treatment	1 / 2	completed
NCT03106415	Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer	Binimetinib Pembrolizumab	treatment	1 / 2	completed
NCT05673200	Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer	Cedazuridine Decitabine Paclitaxel Pembrolizumab	treatment	1	suspended
NCT06008275	Neratinib in Combination With Ruxolitinib in Patients With mTNBC	Neratinib Ruxolitinib	health_services_research	0	not_yet_recruiting
NCT04313075	A Compassionate Use Study of Leronlimab in Breast Cancer	Leronlimab	Not Available	Not Available	no_longer_available
NCT06349642	Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform	No drug interventions	Not Available	Not Available	recruiting
NCT02498613	A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	Cediranib Olaparib	treatment	2	active_not_recruiting
NCT04345913	Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer	Copanlisib Eribulin	treatment	1 / 2	active_not_recruiting
NCT03589339	NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy	Hafnium oxide Nivolumab Pembrolizumab	treatment	1	recruiting
NCT05539365	Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer	Benzalkonium Pembrolizumab	treatment	2	not_yet_recruiting
NCT05770531	Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy	Sacituzumab govitecan	treatment	2	suspended
NCT05422794	Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer	Albumin human Paclitaxel Pembrolizumab	treatment	1	suspended
NCT04445844	INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study	Pelareorep Retifanlimab	treatment	2	recruiting
NCT04789668	Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases	Bintrafusp alfa Pimasertib	treatment	1 / 2	completed
NCT06246968	A Study of Pembrolizumab and Cryoablation in People With Breast Cancer	Pembrolizumab	treatment	1	recruiting
NCT03801369	Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer	Capivasertib Ceralasertib Durvalumab Olaparib Selumetinib	treatment	2	recruiting
NCT05742269	Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05451784	Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS	No drug interventions	treatment	1 / 2	recruiting
NCT05093387	SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer	Carboplatin Pembrolizumab	treatment	1	withdrawn
NCT04634747	Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer	No drug interventions	treatment	2	not_yet_recruiting
NCT04348747	Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer	Pembrolizumab	treatment	2	recruiting
NCT04639245	Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	Atezolizumab Cyclophosphamide Fludarabine	treatment	1 / 2	terminated
NCT04320693	Expanded Access for IMMU-132	Sacituzumab govitecan	Not Available	Not Available	approved_for_marketing
NCT02898207	Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer	Olaparib Onalespib	treatment	1	completed
NCT06492759	High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer	Albumin human Benzalkonium Carboplatin Gemcitabine Paclitaxel Pembrolizumab Platinum Proline	treatment	2	not_yet_recruiting
NCT05368506	ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer	Azenosertib	treatment	0	withdrawn
NCT06505018	Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment	No drug interventions	supportive_care	Not Available	recruiting
NCT03941730	Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	Estradiol	treatment	2	active_not_recruiting
NCT05756166	Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer	Benzalkonium Celecoxib Interferon alfa Pembrolizumab Rintatolimod	treatment	1 / 2	recruiting
NCT04664829	The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC	No drug interventions	treatment	1	recruiting
NCT05081492	CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	No drug interventions	treatment	1	terminated
NCT06324240	Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer	No drug interventions	treatment	1	not_yet_recruiting
NCT03606967	Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	2	recruiting
NCT04249167	Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	0	withdrawn
NCT03579472	M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	1	terminated
NCT05318469	Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer	No drug interventions	treatment	1 / 2	recruiting